Managment of Relapsed/Refractory ALL With Inotuzumab During COVID-19. A Casr Report. Mediterr J Hematol Infect Dis [Internet]. 2022 Apr. 28 [cited 2026 May 24];14(1):e2022043. Available from: https://www.mjhid.org/mjhid/article/view/4979